Beta-lactamases with improved properties for therapy
This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
1. A beta-lactamase comprising an amino acid sequence having at least 95% sequence identity with SEQ ID NO: 1 and the following mutations according to Ambler classification:
a polar and neutral hydrophilic residue other than aspartate (D) at position 276, and
one or more mutations selected from the group consisting of: an aromatic hydrophobic residue other than phenylalanine (F) at position 33; a polar and neutral hydrophilic residue other than serine (S) at position 240, a polar and neutral hydrophilic residue other than alanine (A) at position 238; a polar and neutral hydrophilic residue other than serine (S) at position 266; and an aliphatic hydrophobic residue other than threonine (T) at position, 243.
2. The beta-lactamase of claim 1 , wherein the beta-lactamase has a D276N mutation, a S240P mutation, and a F33Y mutation according to Ambler classification.
3. The beta-lactamase of claim 1 , wherein the beta-lactamase has a D276N mutation, a S238T mutation, and a F33Y mutation according to Ambler classification.
4. The beta-lactamase of claim 1 , wherein the beta-lactamase has a D276N mutation, a S266N mutation, and a T243I mutation according to Ambler classification.
5. The beta-lactamase of claim 1 , wherein the polar and neutral hydrophilic residue is selected from asparagine (N), glutamine (Q), serine (S), threonine (T), proline (P), and cysteine (C).
6. The beta-lactamase of claim 1 , wherein the aromatic hydrophobic residue is selected from tryptophan (W) and tyrosine (Y).
7. The beta-lactamase of claim 1 , wherein the aliphatic hydrophobic residue is selected from glycine (G), leucine (L), isoleucine (I), methionine (M), and valine (V).
8. The beta-lactamase of claim 1 , wherein the beta-lactamase hydrolyzes one or more of penicillins and cephalosporins.
9. The beta-lactamase of claim 8 , wherein the penicillin is ampicillin.
10. The beta-lactamase of claim 8 , wherein the cephalosporin is selected from ceftriaxone, cefotaxime, cefozolin, cefoperazone, cefepime, cefuroxime, and ceftazidime.
11. The beta-lactamase of claim 1 , wherein the beta-lactamase has improved catalytic efficiency against cephalosporins as compared to SEQ ID NO: 1.
12. The beta-lactamase of claim 11 , wherein the beta-lactamase has about a 10 fold to about a 1000 fold improved catalytic efficiency against a cephalosporin as compared to SEQ ID NO: 1.
13. The beta-lactamase of claim 12 , wherein the cephalosporin is selected from ceftriaxone, cefotaxime, cefozolin, cefoperazone, cefepime, cefuroxime, and ceftazidime.
14. The beta-lactamase of claim 1 , wherein the beta-lactamase has improved catalytic efficiency against a cephalosporin as compared to P3A.
15. The beta-lactamase of claim 14 , wherein the cephalosporin is selected from cefotaxime, cefepime, and ceftriaxone.
16. The beta-lactamase of claim 1 , wherein the beta-lactamase is active in the GI tract.
17. The beta-lactamase of claim 16 , wherein the beta-lactamase is stable in the small intestine, optionally selected from one or more of the duodenum, jejunum, and ileum.
18. A polynucleotide comprising a polynucleotide sequence encoding the beta-lactamase of claim 1 .
19. A host cell comprising the polynucleotide of claim 18 .
20. A pharmaceutical composition, comprising the beta-lactamase of claim 1 and a pharmaceutically acceptable carrier or excipient.
21. The pharmaceutical composition of claim 20 , wherein the composition is formulated for oral administration, optionally selected from a tablet, multi-particulate sprinkle, and a multi-particulate capsule.
22. A method for preventing an antibiotic-induced adverse effect in the gastrointestinal (GI) tract, comprising administering an effective amount of a beta-lactamase to a patient in need thereof, wherein the beta-lactamase comprises an amino acid sequence having at least 95% sequence identity with SEQ ID NO: 1 and the following mutations according to Ambler classification:
a polar and neutral hydrophilic residue other than aspartate (D) at position 276, and
one or more mutations selected from the group consisting of: an aromatic hydrophobic residue other than phenylalanine (F) at position 33; a polar and neutral hydrophilic residue other than serine (S) rat position 240, a polar and neutral hydrophilic residue other than alanine (A) at position 238; a polar and neutral hydrophilic residue other than serine (S) at position 266; and an aliphatic hydrophobic residue other than threonine (T) at position 243.
23. The method of claim 22 , wherein the polar and neutral hydrophilic residue is selected from asparagine (N), glutamine (Q), serine (S), threonine (T), proline (P), and cysteine (C).
24. The method of claim 22 , wherein the aromatic hydrophobic residue is selected from tryptophan (W) and tyrosine (Y).
25. The method of claim 22 , wherein the aliphatic hydrophobic residue is selected from glycine (G), leucine (L), isoleucine (I), methionine (M), and valine (V).
26. The method of claim 22 , wherein the subject is being administered or will be administered an antibiotic.
27. A method for treating or preventing an antibiotic induced C. difficile infection (CD) and/or a C. difficile -associated disease, comprising administering an effective amount of a beta-lactamase to a patient in need thereof; wherein the beta-lactamase comprises an amino acid sequence having at least 95% sequence identity with SEQ ID NO: 1 and the following mutations according to Ambler classification:
a polar and neutral hydrophilic residue other than aspartate (D) at position 276, and
one or more mutations selected from the group consisting of: an aromatic hydrophobic residue other than phenylalanine (F) at position 33; a polar and neutral hydrophilic residue other than serine (S) at position 240, a polar and neutral hydrophilic residue other than alanine (A) at position 238; a polar and neutral hydrophilic residue other than serine (S) at position 266; and an aliphatic hydrophobic residue other than threonine (T) at position 243.
28. The method of claim 27 , wherein the polar and neutral hydrophilic residue is selected from asparagine (N), glutamine (Q), serine (S), threonine (T), proline (P), and cysteine (C).
29. The method of claim 27 , wherein the aromatic hydrophobic residue is selected from tryptophan (W) and tyrosine (Y).
30. The method of claim 27 , wherein the aliphatic hydrophobic residue is selected from glycine (G), leucine (L), isoleucine (I), methionine (M), and valine (V).
31. The method of claim 27 , wherein the subject is being administered or will be administered an antibiotic.
32. The method of claim 27 , wherein the C. difficile -associated disease is antibiotic-associated diarrhea (AAD).